Form 4: Lifecore Biomedical Insider Aron English Sells Shares

Aron English, along with related entities, reports the sale of Lifecore Biomedical shares at an average price of $7.0012.

Summary

• A Form 4 filing reveals that Aron English, along with 22NW Fund, LP, 22NW, LP, 22NW Fund GP, LLC, and 22NW GP, Inc. (collectively, the 'Reporting Persons'), reported a transaction involving Lifecore Biomedical, Inc. shares.
• On May 13, 2025, 12,334 shares of common stock were sold at a weighted average price of $7.0012.
• The shares were sold in multiple transactions with prices ranging from $7.0000 to $7.0100.
• Following the reported transaction, the Reporting Persons indirectly beneficially own 1,650,240 shares through 22NW Fund, LP.
• The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While insider selling is not inherently bad, it can sometimes create uncertainty among investors.

Negatives

• Aron English and related entities sold a portion of their holdings in Lifecore Biomedical.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence and is closely monitored by regulators and investors for insights into a company's prospects. Form 4 filings are a routine part of this monitoring process.

Stakeholder Impact

• The sale of shares by a significant shareholder could potentially influence investor sentiment.

Key Dates

Keywords

Form 4, Insider Trading, Share Sale, Lifecore Biomedical, LFCR, Aron English, 22NW Fund